Genmab A (GMAB) Non-Current Debt (2019 - 2026)

Genmab A (GMAB) reported Non-Current Debt of $4.9 billion for Q1 2026, up 3724.03% on a YoY basis from $129.0 million in Q1 2025, and down 1.36% quarter-over-quarter from $5.0 billion in Q4 2025.

Genmab A (GMAB) Non-Current Debt (2019 - 2026) Analysis & Trends

Genmab A has reported Non-Current Debt for 4 years, with the latest figure at $4.9 billion in Q1 2026.

  • For the quarter ending Q1 2026, Non-Current Debt rose 3724.03% year-over-year to $4.9 billion; the trailing twelve-month figure through Mar 2026 stood at $4.9 billion (up 3724.03% YoY), and the FY2025 full-year result was $5.0 billion, changed N/A from the prior year.
  • Non-Current Debt for Q1 2026 stood at $4.9 billion, down from $5.0 billion in the prior quarter.
  • The five-year high for Non-Current Debt was $5.0 billion in Q4 2025, with the low at $129.0 million in Q1 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - -
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn 319.10 Mn
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - -
7 Psyence Biomedical 241.78 Bn 241.78 Bn - -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn -
9 Abivax 94.26 Bn 94.26 Bn - -
10 Genmab A 48.34 Bn 46.82 Bn 831.00 Mn 4.93 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 4.93 Bn
Mar 31, 2026 4.93 Bn
Dec 31, 2025 5.00 Bn
Dec 31, 2025 5.00 Bn
Mar 31, 2025 129.00 Mn
Mar 31, 2025 129.00 Mn
Sep 30, 2020 295.00 Mn
Sep 30, 2020 295.00 Mn
Dec 31, 2019 155.00 Mn
Dec 31, 2019 155.00 Mn
Sep 30, 2019 157.61 Mn
Sep 30, 2019 157.61 Mn